EPS for CytoDyn Inc. (CYDY) Expected At $-0.06

June 21, 2018 - By Marie Mckinney

CytoDyn Inc. (OTCMKTS:CYDY) Logo

Analysts expect CytoDyn Inc. (OTCMKTS:CYDY) to report $-0.06 EPS on July, 19. The stock increased 3.26% or $0.015 during the last trading session, reaching $0.475. About 350,098 shares traded or 21.56% up from the average. CytoDyn Inc. (OTCMKTS:CYDY) has 0.00% since June 21, 2017 and is . It has underperformed by 12.57% the S&P500.

CytoDyn Inc., a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection. The company has market cap of $103.88 million. The Company’s lead product under development for HIV infection include PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease. It currently has negative earnings.

CytoDyn Inc. (OTCMKTS:CYDY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.